Altre notizie

AGC to Establish Mammalian cGMP-Compatible Contract Facility for Biopharmaceutical Development and Production at Chiba Plant

– AGC entered the bioscience business in 1985, and launched its biopharmaceutical CDMO (*2) business in 2000, with primary focus on the Japanese market using microorganisms. Biomeva was acquired in 2016 and CMC Biologics in 2017, allowing AGC to realize full-scale entry into the Western biopharmaceutical […]

Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

– (Logo:
1. A collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes i-DPS technology
Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order […]